Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment : A Retrospective Cohort Study

Kojima, Yuichi; Nakakubo, Sho; Takei, Nozomu; Kamada, Keisuke; Yamashita, Yu; Nakamura, Junichi; Matsumoto, Munehiro; Horii, Hiroshi; Sato, Kazuki; Shima, Hideki; Suzuki, Masaru; Konno, Satoshi

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment : A Retrospective Cohort Study

Kojima, Yuichi; Nakakubo, Sho; Takei, Nozomu et al.

Medicina-Lithuania, 2022, 58(4), 513

Permalink : https://hdl.handle.net/2115/85697

このアイテムのアクセス数:371件（2026-03-13 20:09 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.3390/medicina58040513			10

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	metadata only access
URI	https://hdl.handle.net/2115/85697
タイトル	Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment : A Retrospective Cohort Study
著者	Kojima, Yuichi ; Nakakubo, Sho ; Takei, Nozomu ; Kamada, Keisuke ; Yamashita, Yu ; Nakamura, Junichi ; Matsumoto, Munehiro ; Horii, Hiroshi ; Sato, Kazuki ; Shima, Hideki ; Suzuki, Masaru ; Konno, Satoshi
著者名 Kojima, Yuichi
著者名 Nakakubo, Sho
著者名 Takei, Nozomu
著者名 Kamada, Keisuke
著者名 Yamashita, Yu
著者名 Nakamura, Junichi
著者名 Matsumoto, Munehiro
著者名 Horii, Hiroshi
著者名 Sato, Kazuki
著者名 Shima, Hideki
e-Rad_Researcher 10374290 著者名 Suzuki, Masaru
e-Rad_Researcher 20399835 著者名 Konno, Satoshi
言語	英語
キーワード	COVID-19
	tocilizumab
	baricitinib
	retrospective study
発行日	2022-04
出版者	MDPI
収録物名	Medicina-Lithuania
巻(号)	58(4)
ページ	513
抄録	Background and Objectives: Tocilizumab and baricitinib have been observed to improve the outcomes of patients with coronavirus disease 2019 (COVID-19). However, a comparative evaluation of these drugs has not been performed. Materials and Methods: A retrospective, single-center study was conducted using the data of COVID-19 patients admitted to Hokkaido University hospital between April 2020 and September 2021, who were treated with tocilizumab or baricitinib. The clinical characteristics of the patients who received tocilizumab were compared to those of patients who received baricitinib. Univariate and multivariate logistic regression analyses of the outcomes of all-cause mortality and improvement in respiratory status were performed. The development of secondary infection events was analyzed using the Kaplan-Meier method and the log-rank test. Results: Of the 459 patients hospitalized with COVID-19 during the study, 64 received tocilizumab treatment and 34 baricitinib treatment, and those 98 patients were included in the study. Most patients were treated with concomitant steroids and exhibited the same severity level at the initiation of drug treatment. When compared to each other, neither tocilizumab nor baricitinib use were associated with all-cause mortality or improvement in respiratory status within 28 days from drug administration. Conclusions: Age, chronic renal disease and early administration of TCZ or BRT from the onset of COVID-19 were independent prognostic factors for all-cause mortality, whereas anti-viral drug use and the severity of COVID-19 at baseline were associated with an improvement in respiratory status. Secondary infection-free survival rates of patients treated with tocilizumab and those treated with baricitinib did not significantly differ. The results suggest that both tocilizumab and baricitinib could be clinically equivalent agents of choice in treatment of COVID-19.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	1010-660X
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.3390/medicina58040513